Evaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed With Hemophilia A
NCT03932201 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 371
Last updated 2026-04-09
Summary
The aim of the HEM-POWR study is to understand better how Damoctocog alfa pegol (Jivi) is used to treat people with Hemophilia A in day-to-day life, how well the treatment is tolerated and how satisfied patients and physicians are with the treatment.
Conditions
Interventions
- DRUG
-
Damoctocog alfa pegol (Jivi, Bay94-9027)
Follow clinical practice. BAY94-9027 is a B-domain-deleted recombinant factor VIII (rFVIII) product site-specifically conjugated to a single (dual 30-kDa branched) 60-kDa polyethylene glycol (PEG) molecule. BAY 94-9027 is intended for prophylaxis and treatment of bleeds in patients with hemophilia A aged ≥12 years, with a narrow, predictable weekly dose that allows for the treatment regimen to be tailored to individual patient needs.
Sponsors & Collaborators
- lead INDUSTRY
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-10-21
- Primary Completion
- 2026-12-31
- Completion
- 2027-03-31
Countries
- United States
- Belgium
- Brazil
- Canada
- Colombia
- Denmark
- Germany
- Greece
- Italy
- Japan
- Kuwait
- Netherlands
- Norway
- Saudi Arabia
- Slovenia
- Spain
- Sweden
- Switzerland
- Taiwan
- United Arab Emirates
Study Locations
More Related Trials
-
Study to Learn More About the Safety of Drug Jivi Over a Long Period of Time in Previously Treated Patients With Hemophilia A (Bleeding Disorder Resulting From a Lack of FVIII) Who Are Receiving Jivi Regularly at Their Treating Doctors to Prevent Bleeding
NCT04461639 ·Status: ACTIVE_NOT_RECRUITING
-
A Study to Learn More About Treatment With Damoctocog Alfa Pegol, How it is Used in Every Day Practice ("Real-World"), and How Satisfied People Who Receive Damoctocog Alfa Pegol Are in United States (US) Hemophilia Treatment Centers
NCT05395858 ·Status: TERMINATED
-
An Observational Study Called JOIHA to Learn More About How Well the Treatment With Jivi Works to Prevent Problems With Joints in Adults With Hemophilia A.
NCT05643560 ·Status: ACTIVE_NOT_RECRUITING
-
A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A
NCT05911763 ·Status: ACTIVE_NOT_RECRUITING
-
A Study to Learn How Safe the Study Treatment BAY94-9027 is and How it Affects the Body in Previously Treated Children Aged 7 to Less Than 12 Years With Severe Hemophilia A, a Genetic Bleeding Disorder That is Caused by the Lack of a Protein Called Clotting Factor 8 (FVIII) in the Blood
NCT05147662 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
NCT05568719 ·Status: RECRUITING ·Phase: PHASE3
-
Patient Functioning and Well-being, Economic, and Clinical Impact of Hemophilia A and Its Treatment
NCT02396862 ·Status: COMPLETED
-
Assessing Physician and Hemophilia A Patient Reasons and Expectations for Switching Treatment to Kovaltry & Jivi: A Nested Study Within an Existing Registry
NCT03603275 ·Status: TERMINATED
-
Study Evaluating "Real World" Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog Alfa) for Routine Prophylaxis
NCT02830477 ·Status: COMPLETED
-
A Study to Evaluate the Safety and Tolerability of Prophylactic Emicizumab in Hemophilia A Patients With Inhibitors
NCT03191799 ·Status: COMPLETED ·Phase: PHASE3
-
2-cohort Study of Adult Patients With Severe Hemophilia A in Greece
NCT02319070 ·Status: COMPLETED
-
A Prospective Study to Collect High-Quality Documentation of Bleeds, Health-Related Quality of Life (HRQoL), and Safety Outcomes in Patients With Hemophilia A Treated With Standard-of-Care Treatment
NCT02476942 ·Status: COMPLETED
-
Study Evaluating Refacto For Pharmacovigilance
NCT00195442 ·Status: COMPLETED
-
Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B
NCT03938792 ·Status: COMPLETED ·Phase: PHASE3
-
Outcomes of Prophylaxis With Emicizumab in Children With Severe Hemophilia A in Ivory Coast
NCT05279924 ·Status: COMPLETED ·Phase: NA
-
BAY14-2222 Prophylaxis and Joint Function Improvement (Adults)
NCT00586521 ·Status: COMPLETED ·Phase: PHASE4
-
Relative Bioavailability Of Two Formulations Of Moroctocog Alfa (AF-CC)
NCT01579903 ·Status: COMPLETED ·Phase: PHASE1
-
Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog Alfa
NCT06940830 ·Status: RECRUITING ·Phase: PHASE4
-
A Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C≤1%)
NCT03587116 ·Status: COMPLETED ·Phase: PHASE3
-
A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitors
NCT03196284 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy Study of Activated Prothrombin Complex for Prevention of Bleeds in Hemophilia A With Inhibitors
NCT00221195 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A
NCT04158934 ·Status: ACTIVE_NOT_RECRUITING
-
Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia A
NCT06579144 ·Status: RECRUITING ·Phase: PHASE1
-
Hemlibra in Mild Hemophilia A
NCT04567511 ·Status: RECRUITING ·Phase: PHASE4
-
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors
NCT02622321 ·Status: COMPLETED ·Phase: PHASE3